BCA
AVXL icon

Bray Capital Advisors’s Anavex Life Sciences AVXL Stock Holding History

Bray Capital Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-950
Closed -$5.4K – 257
2024
Q3 		$5.4K Hold
950
– – ﹤0.01% 241
2024
Q2 		$4.01K Hold
950
– – ﹤0.01% 240
2024
Q1 		$4.84K Hold
950
– – ﹤0.01% 246
2023
Q4 		$8.85K Hold
950
– – ﹤0.01% 233
2023
Q3 		$6.22K Hold
950
– – ﹤0.01% 238
2023
Q2 		$7.72K Hold
950
– – ﹤0.01% 235
2023
Q1 		$8.14K Hold
950
– – ﹤0.01% 243
2022
Q4 		$8.8K Hold
950
– – ﹤0.01% 243
2022
Q3 		$10K Hold
950
– – ﹤0.01% 256
2022
Q2 		$10K Hold
950
– – ﹤0.01% 246
2022
Q1 		$12K Buy
950
+700
+280% +$8.61K ﹤0.01% 245
2021
Q4 		$4K Buy
+250
New +$4.75K ﹤0.01% 261

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bray Capital Advisors's AVXL Position: Q4 2024 in Review

Bray Capital Advisors sold out of Anavex Life Sciences (AVXL) in Q4 2024, closing a stake of 950 shares — an estimated $5.4K sold.

Bray Capital Advisors first reported a position in AVXL in Q4 2021 and held it in 12 quarters. The position peaked at $12K in Q1 2022. 168 funds tracked by Wall St. Rank hold AVXL as of Q4 2024.

  • Bray Capital Advisors reported no remaining Anavex Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Bray Capital Advisors sold 950 Anavex Life Sciences shares in Q4 2024, an estimated $5.4K.
  • Bray Capital Advisors first reported a position in Anavex Life Sciences in Q4 2021 and held it in 12 quarters.
  • Bray Capital Advisors's Anavex Life Sciences position peaked at $12K in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2024.

Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.